A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a recommended dose(s) and regimen for GDC-1261 for subsequent studies.

Trial Details

NCT ID
NCT07567846
Phase
PHASE1 / PHASE2
Sponsor
Genentech, Inc.
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • GDC-1261
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • Darlinghurst, New South Wales, Australia|-33.87939,151.21925
  • Heidelberg, Victoria, Australia|-37.75,145.06667

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of \<=1
  • Life expectancy is \>= 3 months
  • Histologically or cytologically confirmed prostate adenocarcinoma
  • Disease progression during or following the direct prior line of therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →